Visual function linked to preBCVA in AMD cataract patients

Article

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Related: Radiotherapy system receives CE mark extension

The US investigators studied 4,924 cataract surgeries on eyes with AMD for which preoperative and postoperative NEI-VFQ-25 questionnaires had been submitted. All were from the VA Ophthalmic Surgical Outcomes Data Project. The researchers compared outcomes in these eyes with outcomes in control eyes that did not have retinal pathology, looking at changes in visual acuity and improvement in overall visual function and its subscales.

Analysing overall scores, the investigators found that, for eyes with a preBCVA of ≥20/40, the improvement in visual function was similar to that seen in patients without retinal pathology. If the eye’s preBCVA was <20/40, however, then there was a lesser degree of improvement; the amount of improvement decreased with decreasing preBCVA. 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.